DiaSorin S.p.A. (OTCMKTS:DSRLF – Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 1,000 shares traded hands during trading, an increase of 179% from the previous session’s volume of 359 shares.The stock last traded at $81.00 and had previously closed at $80.00.
Analyst Ratings Changes
DSRLF has been the subject of a number of recent analyst reports. Zacks Research raised DiaSorin to a “hold” rating in a research report on Tuesday, May 12th. BNP Paribas Exane cut DiaSorin from a “neutral” rating to an “underperform” rating in a research note on Tuesday, July 7th. Piper Sandler initiated coverage on DiaSorin in a report on Thursday, June 11th. They issued a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft lowered DiaSorin from a “hold” rating to a “sell” rating in a research note on Wednesday, June 17th. Finally, UBS Group downgraded shares of DiaSorin from a “buy” rating to a “neutral” rating in a report on Thursday, April 9th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.
Read Our Latest Analysis on DSRLF
DiaSorin Stock Up 1.3%
About DiaSorin
DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.
At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.
Featured Stories
- Five stocks we like better than DiaSorin
- Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become
- 3 Refiners Benefiting From Oil Volatility and Tight Fuel Supply
- Carrier Earnings Could Send the Stock to a New All-Time High
- 3 Unique AI Software Plays With Strong Analyst Support
Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.
